Brokerages Set Masimo Co. (NASDAQ:MASI) Target Price at $179.67

Masimo Co. (NASDAQ:MASI) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $179.67.

MASI has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Wells Fargo & Company upped their target price on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. BTIG Research increased their price target on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Piper Sandler boosted their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd.

Institutional Investors Weigh In On Masimo

Hedge funds and other institutional investors have recently modified their holdings of the business. NBC Securities Inc. grew its holdings in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 200 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Masimo by 136.5% during the fourth quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after acquiring an additional 269 shares during the period. HHM Wealth Advisors LLC raised its stake in shares of Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Masimo in the second quarter valued at approximately $109,000. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Price Performance

MASI stock opened at $171.23 on Wednesday. The company has a market capitalization of $9.17 billion, a PE ratio of 118.09 and a beta of 1.01. The company’s fifty day moving average price is $165.55 and its 200-day moving average price is $137.44. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a one year low of $101.61 and a one year high of $180.97.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.63 EPS. On average, equities analysts anticipate that Masimo will post 4.03 EPS for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.